Literature DB >> 7496964

Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection.

Z X Zhang1, M Chen, A Sönnerborg, M Sällberg.   

Abstract

Antigenic regions within the nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV) were identified and characterized by the use of 127 overlapping synthetic peptides and a serum panel consisting of 167 human serum samples from persons with antibodies to HCV. Initially, 20 anti-HCV-positive serum samples were used to screen the peptides covering the complete NS2 and NS5 proteins. Among the 27 overlapping peptides spanning the NS2 protein of HCV, only the peptide covering residues 960 to 975 was recognized by human sera. Within the 100 peptides covering the NS5 protein, major linear antigenic regions were located at residues 2284 to 2329 within the putative NS5a and at residues 2584 to 2599 and 2944 to 2959 within the putative NS5b. Additional minor linear antigenic regions were also identified within the NS5. The sequence of the antigenic region of the NS2 protein is, unlike most parts of the NS2 protein, highly conserved among the described types of HCV, whereas the sequence of the major antigenic region of NS5 shows variability among HCV types. The recognition of a peptide corresponding to a part of the major region of NS5 was found to be dependent on HCV type. In 129 anti-HCV-positive serum samples, the prevalence of antibodies to the NS2 protein was found to be 23% among HCV RNA-positive sera and 10% among HCV RNA-negative sera. In the same samples, reactivity to the major linear antigenic regions of HCV NS5 was found in 68% of the HCV RNA-positive sera and 67% of the HCV RNA-negative sera. Of 18 serum samples from five patients with acute HCV infections, and who seroconverted with respect to anti-HCV, 4 were found to be reactive to one or more of the 100 NS5 peptides and in three serum samples the NS5 reactivities were found to shorten the time for serodiagnosis of cross-reactive with a region form residues 2584 to 2599 of NS5, which has 67% homology with a six-residue sequence of NS2. In conclusion, in this study we have identified and evaluated the potential use of synthetic peptides corresponding to linear antigenic regions of the NS2 and NS5 proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7496964      PMCID: PMC368250          DOI: 10.1128/cdli.1.3.290-294.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis virus infection.

Authors:  H Okamoto; F Tsuda; A Machida; E Munekata; Y Akahane; Y Sugai; K Mashiko; T Mitsui; T Tanaka; Y Miyakawa
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

2.  Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions.

Authors:  H Okamoto; S Okada; Y Sugiyama; K Kurai; H Iizuka; A Machida; Y Miyakawa; M Mayumi
Journal:  J Gen Virol       Date:  1991-11       Impact factor: 3.891

3.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins.

Authors:  M Sällberg; U Rudén; L O Magnius; E Norrby; B Wahren
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

4.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

5.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

6.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

7.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

8.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.

Authors:  A J Weiner; H M Geysen; C Christopherson; J E Hall; T J Mason; G Saracco; F Bonino; K Crawford; C D Marion; K A Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes.

Authors:  H Okamoto; K Kurai; S Okada; K Yamamoto; H Lizuka; T Tanaka; S Fukuda; F Tsuda; S Mishiro
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

10.  The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA.

Authors:  P J Chen; M H Lin; K F Tai; P C Liu; C J Lin; D S Chen
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

View more
  5 in total

1.  Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies.

Authors:  Hubert Darius J Daniel; Priya Abraham; Sukanya Raghuraman; Perumal Vivekanandan; Thenmozhi Subramaniam; Gopalan Sridharan
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection.

Authors:  G V Gregorio; K Choudhuri; Y Ma; P Pensati; R Iorio; P Grant; J Garson; D P Bogdanos; A Vegnente; G Mieli-Vergani; D Vergani
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

3.  Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein.

Authors:  M Chen; A Sönnerborg; M Sällberg
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

4.  Antigenic structure of the hepatitis C virus envelope 2 protein.

Authors:  Z X Zhang; A Sönnerborg; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

5.  Antigenic heterogeneity of the hepatitis C virus NS5A protein.

Authors:  Xiao-Guang Dou; Ganesh Talekar; Joy Chang; Xing Dai; Lixia Li; Maria-Teresa Bonafonte; Brian Holloway; Howard A Fields; Yury E Khudyakov
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.